Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samer Al Hadidi

Showing results (71-80 of 94) with videos related to

Pageof 10
Sort By:
The Journal of Clinical Investigation|October 26, 2023
BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesionsFumou Sun, Yan Cheng, Jin-Ran Chen, et al.
JAMA Oncology|June 5, 2025
Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols: A Secondary Analysis of 3 Clinical TrialsSamer Al Hadidi, Obada Ehab Ababneh, Carolina D Schinke, et al.
Blood Advances|December 5, 2023
Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-upSamer Al Hadidi, Obada Ehab Ababneh, Carolina D Schinke, et al.
JNCI Cancer Spectrum|November 25, 2023
Characteristics of post hoc subgroup analyses of oncology clinical trials: a systematic reviewJawad Alrawabdeh, Marah Alzu'bi, Muntaser Alzyoud, et al.
Blood Advances|August 17, 2022
Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell levelCarolina Schinke, Alexandra M Poos, Michael Bauer, et al.
British Journal of Haematology|January 2, 2026
Inconsistent definitions of transplant ineligibility in multiple myeloma: A systematic reviewKarun Neupane, Mitch Singstock, Darshi Shah, et al.
Cancer Biomarkers : Section a of Disease Markers|June 9, 2025
Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myelomaFumou Sun, Yan Cheng, Catherine Ma, et al.
The Oncologist|September 5, 2024
Evaluating early intervention in smoldering myeloma clinical trials: a systematic reviewApoorva Kakkilaya, Aaron Trando, Edward R Scheffer Cliff, et al.
Blood Cancer Journal|November 7, 2025
Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world studySamer Al Hadidi, Aniko Szabo, Bhavesh Mohan Lal, et al.
Bone Marrow Transplantation|November 8, 2023
Upfront allogeneic transplantation versus JAK inhibitor therapy for patients with myelofibrosis: a North American collaborative studyDawn Maze, Murat O Arcasoy, Ryan Henrie, et al.
Pageof 10

Showing results (71-80 of 94) with videos related to

Sort By:
Pageof 10
The Journal of Clinical Investigation|October 26, 2023
BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesionsFumou Sun, Yan Cheng, Jin-Ran Chen, et al.
JAMA Oncology|June 5, 2025
Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols: A Secondary Analysis of 3 Clinical TrialsSamer Al Hadidi, Obada Ehab Ababneh, Carolina D Schinke, et al.
Blood Advances|December 5, 2023
Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-upSamer Al Hadidi, Obada Ehab Ababneh, Carolina D Schinke, et al.
JNCI Cancer Spectrum|November 25, 2023
Characteristics of post hoc subgroup analyses of oncology clinical trials: a systematic reviewJawad Alrawabdeh, Marah Alzu'bi, Muntaser Alzyoud, et al.
Blood Advances|August 17, 2022
Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell levelCarolina Schinke, Alexandra M Poos, Michael Bauer, et al.
British Journal of Haematology|January 2, 2026
Inconsistent definitions of transplant ineligibility in multiple myeloma: A systematic reviewKarun Neupane, Mitch Singstock, Darshi Shah, et al.
Cancer Biomarkers : Section a of Disease Markers|June 9, 2025
Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myelomaFumou Sun, Yan Cheng, Catherine Ma, et al.
The Oncologist|September 5, 2024
Evaluating early intervention in smoldering myeloma clinical trials: a systematic reviewApoorva Kakkilaya, Aaron Trando, Edward R Scheffer Cliff, et al.
Blood Cancer Journal|November 7, 2025
Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world studySamer Al Hadidi, Aniko Szabo, Bhavesh Mohan Lal, et al.
Bone Marrow Transplantation|November 8, 2023
Upfront allogeneic transplantation versus JAK inhibitor therapy for patients with myelofibrosis: a North American collaborative studyDawn Maze, Murat O Arcasoy, Ryan Henrie, et al.
Pageof 10